drugset / Trial / NCT00784186

Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial

NCT00784186

Completed 120 enrolled Gynuity Health Projects
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 260 women comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.

Timeline

Start
2008-08
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifepristone Small molecule 200 mg
Background Misoprostol Other / unclassified 800 ug Other

Indications

No indication recorded.